ESG
Johnson & Johnson sets high standards for health equity and social impact through local resource investment
ESG: Deborah Guion, Head of Health Equity at Johnson & Johnson Australia and New Zealand, delved into the company’s dynamic journey towards prioritising health equity and social impact.
In this interview with Health Industry Hub, Ms Guion who heads up the role for J&J MedTech and J&J Innovative Medicine (previously Janssen) locally, highlighted several key factors driving the outcomes of the recently released ANZ Impact Report.
Ms Guion stressed the importance of senior leadership commitment in driving health equity and social impact, saying “Last year, our two managing directors, Sue Martin and Urs Voegeli took time to travel to Arnhem Land with me, and they sat and listened to community talk about the challenges they face.”
Shedding light on the initiatives with the most profound outcomes, she delved into Johnson & Johnson’s strategy for involving employees in social impact projects, emphasising the significance of cultivating a culture of shared responsibility.
When confronted with the inevitable challenges of driving social and community impact, Ms Guion acknowledged the complexities involved but emphasised the importance of persistence and adaptability.
Looking towards the future, Ms Guion highlighted the emerging trends in health equity and social impact within the industry. She emphasised the increasing integration of data-driven approaches, as well as the growing emphasis on partnerships and collective action to address pressing societal challenges.
“It is a great opportunity for knowledge sharing across the sector because ultimately, the community work that each of us are doing is for the greater benefit of humanity,” she stated.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.
The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.
Medical
NSW Health to settle ‘largest’ class action
A class action alleging NSW Health underpaid clinicians has settled after the department agreed to a payout of nearly a […]
MoreNews & Trends - Pharmaceuticals
Lilly’s first-in-class therapy PBS listed for early breast cancer after 15-year gap
Pharma News: Australians diagnosed with early-stage breast cancer, particularly those at high risk of recurrence, will gain access to the […]
MoreNews & Trends - Pharmaceuticals
AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases
Pharma News: AstraZeneca has scored four positive Pharmaceutical Benefits Advisory Committee (PBAC) recommendations following the March meeting. These recommendations, spanning […]
MoreNews & Trends - Pharmaceuticals
PBAC recommendation to reshape prescribing in heart failure
Pharma News: Aligned with the government’s Scope of Practice Review, the Pharmaceutical Benefits Advisory Committee (PBAC) has made a practice-changing […]
More